Skip to main content
All lobbying filings

CGCN GROUP, LLC

Lobbying for FRESENIUS KABI USA, LLC · Healthcare company

 Filing Registration
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Sep 4, 2025
Money reported
None
Registrations and no-activity reports carry no figure.
Client based in
Illinois

Official filing document

 Lobbyists on this filing 1
  • MARTHA BEATRICE MILLER New on this filing
    Previously held: Confidential Assistant, U.S. Department of Education, 2017-2019; Deputy Director of Scheduling, Sen. Ted Cruz (TX), 2019-2020; Scheduler, Rep. Warren Davidson (OH-08), 2020-2022.

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Lobbying activity 4
Manufacturing

Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements. U.S. manufacturing incentives. Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers. Section 232 investigation into pharmaceuticals and unfair trade practices.

Tariff (miscellaneous tariff bills)

Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements. U.S. manufacturing incentives. Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers. Section 232 investigation into pharmaceuticals and unfair trade practices.

Taxation/Internal Revenue Code

Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements. U.S. manufacturing incentives. Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers. Section 232 investigation into pharmaceuticals and unfair trade practices.

Trade (domestic/foreign)

Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements. U.S. manufacturing incentives. Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers. Section 232 investigation into pharmaceuticals and unfair trade practices.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem